SCHEMBL21652016

SCHEMBL21652016

CC(S)N1CCC(C)(NC(=O)C2(NC(=O)OC(C)(C)C)CCC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.39
CTSL P07711 2/20 0.30
CTSB P07858 1/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20070300 0.90 RET (0.40) RETCTSLCTSBCTSK
SCHEMBL20148062 0.90 RET (0.41) RETCTSLCTSBCTSK
SCHEMBL20070400 0.88 RET (0.40) RETCTSLCTSBCTSK
SCHEMBL20206055 0.87 CTSL (0.34) RETCTSLCTSBCTSK
SCHEMBL20205766 0.85 RET (0.39) RETCTSLCTSBCTSK
SCHEMBL20158649 0.82 RET (0.40) RET
SCHEMBL21465974 0.81 RET (0.42) RETCTSLCTSB
SCHEMBL20158550 0.80 RET (0.42) RETCTSLCTSBCTSK
SCHEMBL20070301 0.78 RET (0.40) RETCTSK
SCHEMBL20158650 0.77 RET (0.38) RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-12-10 US disclosed
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885CTSL 4508/4885CTSB 4378/4885
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885CTSL 4508/4885CTSB 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.